

RETRACTION

# Retraction: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells

The *PLOS ONE* Editors

The authors Min-Jean Yin and Rounak Nassirpour and a Pfizer representative contacted the editorial office to raise that there are image duplications in Figure 4B of this article. Pfizer has undertaken a review and deemed that important conclusions in the manuscript cannot be verified, as original images cannot be located.

In light of the concerns identified, the authors and the *PLOS ONE* Editors retract this article. We did not receive any response or comment from Pramod Mehta.

## Reference

1. Nassirpour R, Mehta PP, Baxi SM, Yin M-J (2013) miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells. *PLoS ONE* 8(4): e62170. doi:[10.1371/journal.pone.0062170](https://doi.org/10.1371/journal.pone.0062170) PMID: [23637992](https://pubmed.ncbi.nlm.nih.gov/23637992/)



## OPEN ACCESS

**Citation:** The *PLOS ONE* Editors (2017) Retraction: miR-221 Promotes Tumorigenesis in Human Triple Negative Breast Cancer Cells. *PLoS ONE* 12(4): e0175869. <https://doi.org/10.1371/journal.pone.0175869>

**Published:** April 10, 2017

**Copyright:** © 2017 The PLOS ONE Editors. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.